Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(β-11C) DOPA and PET

Biological Psychiatry

Volumn 46, Issue 5, 1999, Pages 681-688

  Lindström, Leif H ^a   Gefvert, Ola ^a   Hagberg, Gisela ^b   Lundberg, Tommie ^a   Bergström, Mats ^b   Hartvig, Per ^b   Långström, Bengt ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

11C L DOPA; Dopamine; PET medial prefrontal cortex; Schizophrenia; Striatum

Indexed keywords

DOPAMINE;

ADULT; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; FEMALE; HUMAN; MALE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; CORPUS STRIATUM; DOPAMINE; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PREFRONTAL CORTEX; SCHIZOPHRENIA; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0032802997     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00109-2     Document Type: Article

References (47)

1. Abi-Dargham A., Gil R., Krystal J., Baldwin R., Seibul J., Bowers M., et al. Increased striatal dopamine transmission in schizophrenia confirmation in a second cohort . Am J Psychiat. 155:1998;761-767.
2. 11C-L-DOPA in healthy volunteers and patients with unipolar major depression. Depression. 1:1992;71-81.
3. Anderssson J.L.R., Thurfjell L. Implementation and validation of a fully automatic system for intra- and interindividual registration of PET brain scans. J Comput Assis Tomogr. 12:1997;136-144.
4. Andreasen N.C., Arndt S., Swayze V., Ciyaldo T., Flaum M., Leary O., et al. Thalamic abnormalities visualized through magnetic resonance image averaging. Science. 266:1994;294-298.
5. Angrist B., van Kammen D.P. CNS stimulants as a tool in the study of schizophrenia. Trends Neurosci. 7:1984;388-390.
6. Bergström M., Eriksson L., Bohm C., Blomqvist G., Litton J. Correction for scattered radiation in a ring detector positron camera by integral transformations of the projections. J Comput Assist Tomogr. 7:1983;42-50.
7. Bjerkenstedt L., Edman G., Hagenfeldt L., Sedvall G., Wiesel F.A. Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiat. 147:1985;276-282.
8. 11C-labelled L-tyrosine and L-DOPA. Acta Chem Scand. 44:1990;183-188.
9. Breier A., Su T.-P., Saunders R., Carson R.E., Kolachana B.S., Bartolomeis A., et al. Schizophrenia is associated with elevated amphetamine-induced synaptic concentrations evidence from a novel positron tomography method . Proc Natl Sci USA. 94:1997;2569-2574.
10. Brown R.M., Crane A.M., Goldman P.S. Regional distribution of monoamines in the cerebral cortex and subcortical structures of the rhesus monkey concentration and in vivo synthesis rates . Brain Res. 158:1979;133-150.
11. Carlsson A., Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol. 20:1963;140-144.
12. 3H-tyrosine in living brain is not committed to dopamine synthesis. J Cereb Blood Flow Metab. 18:1998;491-499.
13. Cumming P., Gjedde A. Compartmental analysis of DOPA decarboxylation in living brain from dynamic positron emission tomograms. Synapse. 29:1998;37-61.
14. Dao-Castellana M.H., Paillere-Martinot M.-L., Hantraye P., Attar-Levy D., Remy P., Crouzel C., et al. Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr Res. 23:1997;167-174.
15. Descarries L., Seguela P., Watkins K. Nonjunctional relationships of monoamine axon terminals in the cerebral cortex of adult rats. Fuxe K., Agnati L.F. Volume Transmission in the Brain Novel Mechanisms for Neural Transmission . 1991;53-62 Raven Press, New York.
16. Edling C., Hellman B., Arvidsson B., Andersson J., Hartvig P., Lilja A., et al. Do organic solvents induce changes in the dopaminergic system? Positron emission tomography studies in occupationally exposed subjects. Int Arch Occup Environ Health. 70:1997;180-186.
17. Fernell E., Watanabe Y., Adolfsson I., Tani Y., Bergström M., Hartvig P., et al. Possible effects of tetrahydrobiopterin treatment in six children with autism - clinical and positron emissions tomography data a pilot study . Dev Med Child Neurol. 39:1997;313-318.
18. Gaser C., Kiebel S., Riehemann S., Volz H.P., Sauer H. Statistical parametric mapping of structural changes in brain-application to schizophrenia research. Neuroimage. 7:1998;S718.
19. Goldman-Rakic P., Selemon L. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr Bull. 23:1997;437-458.
20. Greenblatt M., Solomon H.C. Concerning a theory of frontal lobe functioning. Greenblatt M., Solomon H.C. Frontal lobes and schizophrenia. 1953;391-413 Springer Verlag, New York.
21. Greitz T., Bohm C., Holte S., Eriksson L. A computerized brain atlas construction, anatomical content, and some applications . J Comput Assist Tomogr. 15:1991;26-38.
22. 11C-DOPA in humans studied by positron emission tomography. J Neural Transm. 86:1991;25-41.
23. Hartvig P., Torstensson R., Tedroff J., Watanabe Y., Fast K.L., Bjurling P., et al. Amphetamine effects on dopamine release and synthesis rate studied in the Rhesus monkey brain by positron emission tomography. J Neural Transm. 104:1997;329-339.
24. Hietaala J., Syvälahti E., Vuorio K., Rakkolainen V., Bergman J., Haaparanta M., et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet. 346:1995;1130-1131.
25. Hietala J., Syvälahti E. Dopamine in schizophrenia. Ann Med. 28:1996;557-561.
26. Hsiao J., Colison J., Bartko J., Doran A., Konicki P.E., Potter W., Pickar D. Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics. Arch Gen Psychiatry. 50:1993;606-614.
27. Ingvar D.H., Franzen G. Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia. Acta Psychiatr Scand. 50:1974;425-462.
28. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci. 93:1996;9235-9240.
29. Levin S. Frontal lobe dysfunctions in schizophrenia II. Impairments of psychological and brain functions . J Psychiatr Res. 18:1984;57-72.
30. 11C-DOPA and its metabolites for the validation of positron emission tomography studies. J Pharm Biomed Anal. 13:1995;361-367.
31. Lindström L.H. Low HVA and normal 5-HIAA levels in CSF in drug-free schizophrenic patients compared to healthy volunteers correlations to symptomatology and family history . Psychiatr Res. 14:1985;265-272.
32. Matthysse S. Dopamine and the pharmacology of schizophrenia the state of the evidence . J Psychiatr Res. 11:1974;107-113.
33. Patlak C.S., Blasberg R.G. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab. 5:1985;584-590.
34. Quitkin F., Rifkin A., Klein D. Neurologic soft signs in schizophrenia and character disorders. Arch Gen Psychiatr. 33:1976;845-853.
35. Reynolds G.P. Beyond the dopamine hypothesis the neurokemical pathology of schizophrenia . Br J Psychiat. 155:1989;305-316.
36. Reith J., Benkelfat C., Shervin A., Yasuhara Y., Kuwabara H., Andermann F., et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Nat Acad Sci USA. 91:1994;11651-11654.
37. Seidman L.J. Schizophrenia and brain dysfunction an integration of recent neurodiagnostic findings . Psychol Bull. 94:1983;195-238.
38. Tedroff J., Torstensson R., Hartvig P., Lindner K.J., Watanabe Y., Bjurling P., et al. L-DOPA modulates striatal dopaminergic function in vivo evidence from PET investigations in nonhuman primates . Synapse. 25:1997;56-61.
39. Tedroff J., Aquilonius S.M., Hartvig P., Långström B. Functional positron emission tomographic studies of striatal dopaminergic activity. Changes induced by drugs and nigrostriatal degeneration. Adv Neurol. 69:1996;443-448.
40. Thurfjell L., Bohm C., Bengtsson E. CBA - An atlas based software tool used to facilitate the interpretation of neuroimaging data. Comput Programs Biomed. 4:1995;51-71.
41. Torstenson R., Hartvig P., Långström B., Bastami S., Antoni G., Tedroff J. Effect of apomorphine infusion on dopamine synthesis rate relates to dopaminergic tone. Neuropharmacology. 37:1998;989-995.
42. Tuckwell H.C., Koziol J.A. A meta-analysis of homovanillic acid concentrations in schizophrenia. Int J Neurosci. 73:1993;109-114.
43. van Rossum J.M. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther. 160:1966;492-494.
44. Weinberger D.R., Wagner R.L., Wyatt R.J. Neuropathological studies of schizophrenia a selective review . Schizophr Bull. 9:1983;193-212.
45. Weinberger D.R. CAT-scan findings in schizophrenia speculation on the meaning of it all . J Psychiatr Res. 18:1984;477-490.
46. Weinberger D.R., Berman K.F., Zec R.F. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I regional cerebral blood flow evidence . Arch Gen Psychiatr. 43:1986;114-124.
47. Wieselgren I.-M., Lindström L. CSF-levels of HVA and 5-HIAA in drug-free schizophrenic patients and healthy controls a prospective study focused on their predictive value for outcome in schizophrenia . Psychiatr Res. 81:1998;101-110.